FluGen raises $12 million in financing

Freeman Staff

Aug. 25, 2015

MADISON - FluGen Inc., a biotechnology company developing a “universal” influenza vaccine, announced Tuesday it completed a $12 million series A financing.

Venture Investors LLC, the Wisconsin Alumni Research Foundation, the state of Wisconsin Investment Board, and other new investors participated in this first institutional financing of the company, along with many of FluGen’s existing investors led by Knox LLC.

Funds raised will support the continued development of FluGen’s lead universal influenza vaccine candidate, REDEE FLU, including completion of an initial human clinical trial and the preparation of a quadrivalent vaccine candidate.